ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Timolol 5 mg/ml eye drops, solution
Drug: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Drug: Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension

First Posted Date: 2006-04-13

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 523

Registration Number: NCT00314158

Locations: 🇺🇸
United States Investigative Sites, Fort Worth, Texas, United States

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)

First Posted Date: 2006-04-13

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 437

Registration Number: NCT00314171

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Phase 4

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: VIGAMOX

First Posted Date: 2006-04-10

Last Posted Date: 2012-11-02

Lead Sponsor: Alcon Research

Target Recruit Count: 137

Registration Number: NCT00312338

Locations: 🇺🇸
Multiple Locations, Fort Worth, Texas, United States

A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma, Open-angle
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution
Drug: Latanoprost 0.005%/Timolol 0.005% ophthalmic solution

First Posted Date: 2006-04-06

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 408

Registration Number: NCT00311389

Locations: 🇧🇪
European Facilitiies, Puurs, Belgium

Anecortave Acetate Risk-Reduction Trial (AART)

Phase 3

Terminated

Conditions: Dry AMD

Interventions: Drug: Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-03-28

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 2596

Registration Number: NCT00307398

Locations: 🇺🇸
Study Centers in the United States and Globally, Fort Worth, Texas, United States

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

First Posted Date: 2006-03-08

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 30

Registration Number: NCT00300079

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-03-07

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 240

Registration Number: NCT00299507

Locations: 🇺🇸
Alcon Study Sites, Fort Worth, Texas, United States

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Other: Timolol Vehicle
Drug: Timolol 0.5% Ophthalmic Solution

First Posted Date: 2006-02-20

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 173

Registration Number: NCT00293800

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Other: Timolol Vehicle
Drug: Timolol Maleate Ophthalmic Solution 0.5%

First Posted Date: 2006-02-20

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 156

Registration Number: NCT00293787

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Open-angle Glaucoma

Interventions: Drug: Travoprost (TRAVATAN)
Drug: Travoprost, Investigational

First Posted Date: 2006-02-20

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 109

Registration Number: NCT00293761

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy